Windward Bio...announced that the first patients have been dosed in the Phase 2 SIRIUS study of WIN378, the company's ultra long-acting anti-TSLP monoclonal antibody, in patients with chronic obstructive pulmonary disease (COPD) (GlobeNewswire) - Jun 9, 2026 - "SIRIUS is a global, Phase 2, randomized, double-blind, placebo-controlled, dose-finding study. It is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of WIN378 in patients with moderate-to-severe COPD."
Trial status • Chronic Obstructive Pulmonary Disease • Immunology
|